Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 6/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583709 | 0.91 | POLB (0.35) | POLBMDM2 | |
| SCHEMBL6584708 | 0.91 | AKR1C3 (0.41) | POLBMDM2 | |
| SCHEMBL6582612 | 0.90 | OXTR (0.39) | GHSRPOLBMDM2 | |
| SCHEMBL6582733 | 0.85 | AVPR2 (0.38) | GHSRPOLB | |
| SCHEMBL4590180 | 0.83 | BRD4 (0.40) | GHSRPDK2 | |
| SCHEMBL5353210 | 0.82 | AVPR1A (0.43) | GHSRMDM2PDK2 | |
| SCHEMBL4588792 | 0.82 | CASP3 (0.38) | GHSRMDM2PDK2 | |
| SCHEMBL2502274 | 0.81 | AVPR1A (0.45) | POLB | |
| SCHEMBL6585299 | 0.78 | OXTR (0.40) | POLB | |
| SCHEMBL6585126 | 0.77 | GSK3A (0.35) | HSP90AA1POLBMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259505-B1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI SYNTHELABO (FR) | 2004-05-19 | — | — | EP | disclosed |
| US-6596732-B2 | Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors. hormone known for its antidiuretic effect and its effect in regulating arterial pressure. | SANOFI-SYNTHELABO (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | AVPR2, AVPR1B, AVPR1A | GHSR 99/4885HSP90AA1 2900/4885HSP90AB1 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.